Azur acquires rights to Elan chronic pain drug

Thu, 03/11/2010 - 8:17am
The Associated Press

Azur Pharma Ltd. said Thursday that it has agreed to buy the chronic-pain drug Prialt from fellow Irish drugmaker Elan Pharmaceuticals.

Terms of the deal were not disclosed.

Azur said it acquired worldwide rights other than in Europe. The drug generated about $20 million in U.S. sales last year. Patents covering Prialt expire in December 2016, and Azur said in a statement it believes the drug will grow "with continued investment."

Elan Pharmaceuticals Inc. is a subsidiary of Elan Corp. Plc. Shares of Elan rose 8 cents to $7.33 in Thursday afternoon trading.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.